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INTRODUCTION: In BCR-ABL1-negative myeloproliferative neoplasms,
myelofibrosis (MF) is either primary (PMF) or secondary (SMF) to polycythemia
vera or essential thrombocythemia. MF is characterized by an increased risk of
transformation to acute myeloid leukemia (AML) and a shortened life expectancy.
METHODS: Because natural histories of PMF and SMF are different, we studied by
targeted next generation sequencing the differences in the molecular landscape of
86 PMF and 59 SMF and compared their prognosis impact.
RESULTS: PMF had more ASXL1 (47.7%) and SRSF2 (14%) gene mutations than
SMF (respectively 27.1% and 3.4%, P = .04). Poorer survival was associated with
RNA splicing mutations (especially SRSF2) and TP53 in PMF (P = .0003), and with
ASXL1 and TP53 mutations in SMF (P < .0001). These mutations of poor prognosis
were associated with biological features of scoring systems (DIPSS and MYSEC-PM
score). Mutations in TP53/SRSF2 in PMF or TP53/ASXL1 in SMF were more
frequent as the risk of these scores increased. This allowed for a better stratification
of MF patients, especially within the DIPSS intermediate-1 risk group (DIPSS) or the
MYSEC-PM high risk group. AML transformation occurred faster in SMF than in
PMF and patients who transformed to AML were more SRSF2-mutated and less
CALR-mutated at MF sampling.
CONCLUSIONS: PMF and SMF have different but not specific molecular profiles
and different prognosis depending on the molecular profile. This may be due to
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